Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by PAUL F MANSFIELD and JAFFER A AJANI.
PAUL F MANSFIELD
Connection Strength
5.777
JAFFER A AJANI
  1. Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology. Cancer. 2024 Sep 17.
    View in: PubMed
    Score: 0.247
  2. Updated Analysis of a Phase 2 Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Peritoneal Carcinoma from Gastric Cancer. Ann Surg Oncol. 2024 May; 31(5):2824-2825.
    View in: PubMed
    Score: 0.236
  3. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):52-4.
    View in: PubMed
    Score: 0.193
  4. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2021 Jan; 28(1):258-264.
    View in: PubMed
    Score: 0.184
  5. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998 Jul-Aug; 4(4):269-74.
    View in: PubMed
    Score: 0.160
  6. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. 2017 Oct; 24(11):3338-3344.
    View in: PubMed
    Score: 0.151
  7. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget. 2017 Oct 06; 8(46):81430-81440.
    View in: PubMed
    Score: 0.150
  8. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018 01; 32(1):512.
    View in: PubMed
    Score: 0.149
  9. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2017 Aug; 24(8):2291-2301.
    View in: PubMed
    Score: 0.143
  10. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol. 2016 06; 23(6):1948-55.
    View in: PubMed
    Score: 0.136
  11. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016 Jan; 113(1):29-35.
    View in: PubMed
    Score: 0.134
  12. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2016 Jan; 23(1):156-62.
    View in: PubMed
    Score: 0.130
  13. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90.
    View in: PubMed
    Score: 0.128
  14. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81.
    View in: PubMed
    Score: 0.128
  15. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51.
    View in: PubMed
    Score: 0.105
  16. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):417-25.
    View in: PubMed
    Score: 0.091
  17. Patient with advanced gastric cancer responds twice to the same systemic therapy. Gastrointest Cancer Res. 2009 May; 3(3):115-7.
    View in: PubMed
    Score: 0.085
  18. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007 Sep 01; 110(5):989-95.
    View in: PubMed
    Score: 0.076
  19. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Jul; 14(7):2010-7.
    View in: PubMed
    Score: 0.073
  20. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80.
    View in: PubMed
    Score: 0.072
  21. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006 Oct 01; 107(7):1475-82.
    View in: PubMed
    Score: 0.071
  22. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
    View in: PubMed
    Score: 0.064
  23. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005 Feb 20; 23(6):1237-44.
    View in: PubMed
    Score: 0.064
  24. ASO Visual Abstract: Survival Outcomes for Patients Who Have Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol. 2024 Dec; 31(13):9063-9064.
    View in: PubMed
    Score: 0.063
  25. HIPEC for metastatic gastric cancer: Moving the needle towards 3-year survival. Eur J Surg Oncol. 2024 Oct 25; 51(1):108790.
    View in: PubMed
    Score: 0.062
  26. Phase 1 Trial of Total Neoadjuvant Therapy With Short-Course Chemoradiotherapy Followed by Chemotherapy for Patients With Potentially Resectable Gastric Cancer. Int J Radiat Oncol Biol Phys. 2024 Sep 04.
    View in: PubMed
    Score: 0.062
  27. Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol. 2024 Oct; 31(10):6918-6930.
    View in: PubMed
    Score: 0.061
  28. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004 Jul 15; 22(14):2774-80.
    View in: PubMed
    Score: 0.061
  29. Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma. Cancers (Basel). 2023 Oct 25; 15(21).
    View in: PubMed
    Score: 0.058
  30. Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2023 Aug; 30(8):4936-4945.
    View in: PubMed
    Score: 0.056
  31. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003; 21(4):223-7.
    View in: PubMed
    Score: 0.055
  32. Adenocarcinoma of the stomach in patients age 35 years and younger: no impact of early diagnosis on survival outcome. J Surg Oncol. 2002 Nov; 81(3):118-24; discussion 124-5.
    View in: PubMed
    Score: 0.054
  33. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):16-8.
    View in: PubMed
    Score: 0.052
  34. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002 Feb 01; 94(3):641-6.
    View in: PubMed
    Score: 0.051
  35. Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. J Natl Compr Canc Netw. 2021 Oct 22; 1-12.
    View in: PubMed
    Score: 0.050
  36. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 10 01; 274(4):544-548.
    View in: PubMed
    Score: 0.050
  37. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001 Jul; 8(6):519-24.
    View in: PubMed
    Score: 0.049
  38. Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery. 2021 10; 170(4):1231-1239.
    View in: PubMed
    Score: 0.049
  39. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6638-6648.
    View in: PubMed
    Score: 0.048
  40. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol. 2021 Mar; 123(4):911-922.
    View in: PubMed
    Score: 0.048
  41. Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. Surg Endosc. 2021 12; 35(12):6577-6582.
    View in: PubMed
    Score: 0.047
  42. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med. 2020 Oct 29; 9(11).
    View in: PubMed
    Score: 0.047
  43. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer. 2020 Sep; 20(3):313-327.
    View in: PubMed
    Score: 0.047
  44. Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol. 2020 Dec; 122(7):1373-1382.
    View in: PubMed
    Score: 0.047
  45. Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2020 Dec; 27(13):5047-5056.
    View in: PubMed
    Score: 0.046
  46. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol. 2021 Feb; 28(2):758-765.
    View in: PubMed
    Score: 0.046
  47. Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. Ann Surg Oncol. 2020 Dec; 27(13):4963-4969.
    View in: PubMed
    Score: 0.046
  48. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg. 2021 06; 25(6):1380-1387.
    View in: PubMed
    Score: 0.046
  49. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432.
    View in: PubMed
    Score: 0.046
  50. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg. 2020 08; 110(2):398-405.
    View in: PubMed
    Score: 0.045
  51. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol. 2020 Feb 17; 18(1):39.
    View in: PubMed
    Score: 0.045
  52. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2020 Aug; 27(8):2806-2811.
    View in: PubMed
    Score: 0.045
  53. IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol. 2020 May-Jun; 5(3):369-376.
    View in: PubMed
    Score: 0.044
  54. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg. 2020 05; 24(5):1018-1025.
    View in: PubMed
    Score: 0.044
  55. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol. 2019 Dec; 120(8):1350-1357.
    View in: PubMed
    Score: 0.044
  56. Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Ann Surg Oncol. 2020 Feb; 27(2):534-542.
    View in: PubMed
    Score: 0.044
  57. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 1999 Aug; 17(8):2403-11.
    View in: PubMed
    Score: 0.043
  58. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26(11):3602-3610.
    View in: PubMed
    Score: 0.043
  59. Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. Gastric Cancer. 1999 May; 2(1):1-7.
    View in: PubMed
    Score: 0.042
  60. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999 Mar; 229(3):303-8.
    View in: PubMed
    Score: 0.042
  61. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am. 1999 Mar-Apr; 5(2):112-4.
    View in: PubMed
    Score: 0.042
  62. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. 2019 May; 26(5):1394-1400.
    View in: PubMed
    Score: 0.042
  63. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 11; 22(11):2013-2019.
    View in: PubMed
    Score: 0.040
  64. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol. 2018 Sep; 25(9):2720-2730.
    View in: PubMed
    Score: 0.040
  65. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018 Jun; 117(8):1721-1728.
    View in: PubMed
    Score: 0.040
  66. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018 Jul; 118(1):61-67.
    View in: PubMed
    Score: 0.040
  67. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018 Jul; 25(7):2012-2017.
    View in: PubMed
    Score: 0.040
  68. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer. 2018 11; 21(6):1004-1013.
    View in: PubMed
    Score: 0.040
  69. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. 2018 08; 22(8):1325-1333.
    View in: PubMed
    Score: 0.040
  70. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018 03 01; 124(5):998-1007.
    View in: PubMed
    Score: 0.039
  71. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol. 2017 Dec; 8(6):1009-1017.
    View in: PubMed
    Score: 0.039
  72. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. 2017 Oct; 21(10):1563-1570.
    View in: PubMed
    Score: 0.038
  73. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):660-666.
    View in: PubMed
    Score: 0.038
  74. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018 Jan; 21(1):74-83.
    View in: PubMed
    Score: 0.037
  75. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2017 Sep; 24(9):2679-2687.
    View in: PubMed
    Score: 0.037
  76. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol. 2017 Apr; 24(4):960-965.
    View in: PubMed
    Score: 0.036
  77. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol. 2016 Oct; 114(5):602-606.
    View in: PubMed
    Score: 0.035
  78. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol. 2016 12; 23(13):4332-4337.
    View in: PubMed
    Score: 0.035
  79. Laparoscopic staging for gastric cancer. Surgery. 1996 Jun; 119(6):611-4.
    View in: PubMed
    Score: 0.035
  80. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol. 2016 Feb; 23(2):626-32.
    View in: PubMed
    Score: 0.033
  81. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7.
    View in: PubMed
    Score: 0.033
  82. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995 Mar-Apr; 19(2):216-20.
    View in: PubMed
    Score: 0.032
  83. Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. J Infus Chemother. 1995; 5(3):104-11.
    View in: PubMed
    Score: 0.031
  84. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):581-6.
    View in: PubMed
    Score: 0.025
  85. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):167-72.
    View in: PubMed
    Score: 0.020
  86. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008; 47(3):421-7.
    View in: PubMed
    Score: 0.019
  87. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):741-7.
    View in: PubMed
    Score: 0.019
  88. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):656-63.
    View in: PubMed
    Score: 0.016
  89. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.